outperform price
report earn strong jakafi perform
rais sale guidanc -- driven part strong adopt
steroid-refractori gvhd opex lower expect
bottom-lin beat importantli -- share trade
print bode well rest sector
report come week
full note perform slide /updat outlook
pv
 jakafi yoy qoq beat
consensu growth mf penetr
penetr
expect uptak srgvhd pv growth aid
guidanc rais jakafi price
increas oct reiter lt guidanc
growth driver emerg itacitinib gvhd
ye- could add hundr million annual revenu
studi topic rux start atop derm
vitiligo data respect unclear
pemigatinib antibodi program find
compel nich respect competit market
enough face challeng build
portfolio sustain growth beyond jakafi express
readi acquir new asset add oncolog
portfolio howev look asset
contribut around time jakafi patent expiri
may hard figur today right asset
lower reflect adjust estim
increas opex spend lower termin growth
rate part reflect recent commentari
heard gvhd specialist role itacitinib
pleas see analyst certif import disclosur page report evercor isi affili seek busi
compani cover research report investor awar firm may conflict interest could affect
object report investor consid report singl factor make invest decis
jakafi franchis deepli entrench mf/pv
strong growth outlook
relianc jakafi chang reimburs
world franchis that run time
jakafi pois continu growth y/i growth
drug still room run mf penetr well pv
penetr long-term jakafi guidanc remain
billion potenti upsid ip
sever late-stag shot goal includ
meaning opportun gvhd topic jaki
sever pivot program evalu jaki gvhd steroid
refractori steroid nave patient includ itacitinib set
potenti oppi data expect topic rux address larg
unmet need derm fgfri could muscl past
still plenti year left build pipelin
inci strong growth outlook clean balanc sheet give compani
plenti time continu diversifi jakafi even beyond current
portfolio compani activ look way extend domin
mf indic final recogn begun
scratch surfac potenti jaki displac steroid countless
jakafi compris inci revenu patent expiri
product concentr signific concern drug price legisl
could meaning impact slightli less revenu
part well introduct fedratinib mf could disrupt inci
risk pipelin still way go off-set jakafi
jakafi approv sr-agvhd announc posit data
pbo control sr-agvhd trial howev larger opportun
agvhd still remain uncertain may compel
compani suggest similarli face commerci challeng
topic rux vitiligo atop dermat jaki field overal
becom increasingli competit gave leadership posit
show money spend remain high
despit strong top-lin perform spend aggress
limit profit profit margin ex
gain strip stock-bas comp pro-forma result
grossli inappropri view limit patent life left jakafi
investor excess depend pipelin product asid
jakafi disappoint
catalyst timelin beyond
major event data itacitinib agvhd ye
chang fair valu
yoy growth total
yoy growth mf
yoy growth pv
comment call neg impact
inventori normal
inventori normal
inventori normal
inventori normal
increas lower end
increas low end
extend mo
approv sr-agvhd
sale reflect
bari data atop
dermat expect
derm result medic
year
decis longer
particip co-
fund develop
baricitinib
derm result later
year longer
multipl jak combo underway mf itacitinib pim
multipl jak combo underway mf itacitinib pim
multipl jak combo underway mf itacitinib pim
multipl jak combo underway mf itacitinib pim
snda accept prioriti review extend may
expect
snda accept prioriti review extend may
expect
expect
expect
vitiligo on-going data expect
initi studi design reveal
present full atop derm expect top-line result
studi initi sle sever
alopecia areata psoriat arthriti prepar
present full atop derm expect top-line result
studi initi sle sever
present full atop derm expect top-line result
studi initi sle sever
present full atop derm expect top-line result
studi initi sle sever
baricitinib olumi
citadel program monotherapi fl mzl mcl continu
citadel program monotherapi fl mzl mcl continu
citadel program monotherapi fl mzl mcl continu data
citadel program monotherapi fl mzl mcl continu data
on-going result expect
on-going result expect
on-going result expect
on-going result expect
nda submiss expect cholangiocarcinoma
recruit patient pivot trial cholangiocarcinoma
launch pivot bladder program initi tumor-
nda submiss expect cholangiocarcinoma
recruit patient pivot trial cholangiocarcinoma
launch pivot bladder program initi tumor-
nda submiss expect cholangiocarcinoma
recruit patient pivot trial cholangiocarcinoma
launch pivot bladder program initi tumor-
recruit patient pivot trial cholangiocarcinoma
launch pivot bladder program initi tumor-
nv submit nda
nv submit nda
nv submit nda
nv submit nda
phase trial on-going present initi preclin data oral
inhibitor
phase trial on-going dose first patient oral inhibitor
phase trial on-going dose first patient oral inhibitor
phase trial on-going dose first patient oral inhibitor
gitr arginas inhibitor clinic develop
gitr arginas inhibitor clinic develop
gitr arginas inhibitor clinic develop
gitr arginas inhibitor clinic develop
note current less
jakafi revenu come
medicar part addit
propos reduct patient co-
pay remov barrier access
increas number patient
therapi
drug price increasingli come focu us show inci revenu breakdown
medicar part medicaid commerci us meaning exposur
inci main revenu sourc jakafi inhibitor current indic myelofibrosi mf polycythemia
vera pv steroid-refractori acut gvhd sr-agvhd guid toward jakafi sale
billion includ sr-agvhd revenu long-term jakafi guidanc billion
patent protect cover composit matter use jakafi expir late
estim us jakafi penetr mf market remain half
use jakafi stop due diseas transform drug intoler half patient nave
still candid drug
estim jakafi penetr pv market remain growth driver drug
receiv approv sr-agvhd may compani expect sale
ruxolitinib off-label use steroid-refractori chronic set approv acut
set annual beyond
new patient seen acut set chronic set chronic patient previous
classifi acut diseas treat earlier acut set fewer chronic patient emerg
jakafi flagship product major revenu still come mf
indic like chang penetr pv continu call
indic uptak gvhd surpass initi expect
although abl treat mf patient jakafi patient remain refractori compani explor
combin approach jakafi address popul
data present appear show ad
parsaclisib provid clinic benefit mf patient
sub-optimal respons rux monotherapi
reduct spleen volum seen patient
patient dose respons
shown spleen length appear rebound
switch daili weekli dose
analyst event compani releas data nearli half mf patient treat itacitinib reduct total
symptom score tss improv hematolog toler combin rux itacitinib compani may abl hone
extent suppress may lead better result
dual pim/jak inhibit shown enhanc ruxolitinib abil block growth mutat express
tumor well limit prolifer progenitor cell
compani also look switch pt sustain releas formul order mitig patent expiri
evalu sustain releas formul ruxolitinib may provid increas efficaci due increas jak coverag
evalu combin approach jakafi order reach patient refractori
jakafi monotherapi compani also evalu sustain releas formul ruxolitinib
may provid better coverag efficaci
domin mf market jakafi howev competitor program indic either
approv develop
spotlight inreb fedratinib
inreb approv mf aug
adult
high-risk primari secondari mf
inreb demonstr reduct
spleen volum improv
total symptom score compar
posit primarili therapi
look maintain domain domin myelofibrosi inreb approv august
competitor remain develop sound launch gener impact
jakafi use primarili patient alreadi stop therapi due tolerance/effect
commerci iclusig indic cml ph eu compani report sale million
guid revenu million
revenu iclusig vs revenu million
partner olumi baricitinib inhibitor indic ra patient fail tnf
therapi olumi also investig atop derm well system lupu erythematosu
toxic concern price drug discount market leader consensu w/w sale
dose approv us milligram dose approv eu
estim olumi ra million
announc call end
co-fund agreement olumi instead
choos re-alloc capit late stage
previous co-fund post-poc
baricitinib develop addit royalti
base tier royalti remain
pro-rat increment royalti calcul
contribut date
report olumi sale receiv base royalti
diversifi away jakafi olumi iclusig made decis
decreas invest olumi re-deploy capit toward late stage pipelin asset
capmatinib inhibitor investig skip nsclc patient current without
nv releas updat data geometri trial nda enabl tabl
compar capmatinib merck kga tepotinib anoth cmet inhibitor
mutat detect liquid biopsi
lbx tissu biopsi tbx
line treatment
comment trial
durat respons dor
note also evalu xalkori
crizotinib nsclc
alter receiv breakthrough therapi
although updat data program
limit data publish indic
patient show evid
antitumor activ confirm pr
nv expect submit nda ye world-wide right capmatinib
nv includ drug one potenti blockbust anticip launch
elig receiv tier world-wide royalti
capmatinib present nice royalti opportun nv plan file nda
ruxolitinib evalu two pbo control studi steroid refractori acut chronic gvhd
first pbo control gvhd studi ruxolitinib inhibitor
studi basi jakafi fda approv sr-agvhd singl cohort studi therefor addit
scrutini may place result trial could read-through pbo control
studi itacitinib inhibitor
sr-agvhd
sr-cgvhd
trial collabor nv basi eu
approv commerci
vs best avail therapi select investig
studi met primari endpoint overal
respons rate orr day
nv plan ex-u regulatori author
releas addit detail upcom medic
trial collabor nv look need
eu approv commerci
vs best avail therapi select investig
primari endpoint overal respons rate orr
met primari endpoint detail regard studi releas upcom
medic confer result releas
although steroid remain treatment option acut chronic gvhd remain opportun
less acut gvhd patient develop steroid dependent/refractori diseas number even
higher chronic gvhd patient
evalu ruxolitinib combin corticosteroid single-arm studi steroid-
refractori agvhd grade diseas bl patient
recent kol webinar gvhd specialist
ask physician approach treat gvhd
ruxolitinib prefer agent relapsed/refractori
durat ruxolitinib treatment variabl
drug often use taper amount steroid
main limit ruxolitinib pt unabl
toler drug becom thrombocytopen
half patient rux day
reduct bl corticosteroid dose
ruxolitinib shown improv respons rate refractori acut gvhd patient
popul without establish therapi
evalu oral inhibitor chronic gvhd
inhibit reduc inflamm downregul pro-inflammatori t-helper cell
respons well increas treg function control immun respons
grant fda breakthrough design orphan drug design
registr trial look complet enrol
patient popul receiv line therapi
shown orr
kdmn inhibitor shown posit respons cgvhd program monitor
itacitinib opportun gvhd
itacitinib inhibitor evalu trial steroid nave patient
repres larger market global opportun new patient sn-agvhd potenti therapi
sn-agvhd
primari endpoint orr day need show
improv key secondari endpoint nonrelaps mortal
nrm month need show reduct
incid acut gvhd patient
sn-cgvhd
start recruit jan
incid de novo chronic gvhd patient
discuss gvhd kol indic doctor comfort corticosteroid therapi may reluct
physician includ itacitinib set unless strong benefit non-relaps mortal observ data even might
dramat expans treat patient beyond current jakafi usag
itacitinib present world-wide opportun gvhd result expect sn-
agvhd
addit program discuss jak pipelin opportun
ulcer coliti uc inflammatori bowel diseas result persist inflamm
digest tract lead tini open sore line colon
patient uc chronic inflammatori immun respons persist primarili colon
inflammatori bowel diseas uc crohn diseas affect million peopl us
itacitinib inhibitor look reduc inflamm inhibit inflammatori
itacitinib look avoid system dose instead compani hope dose
primarili colon poorli absorb low dose molecul aim mimic topic
dose colon
may provid initi data program
anoth inhibitor evalu hidraden suppurativa ha inflammatori diseas affect sweat
gland drug evalu studi
preval diseas global popul could repres market opportun
inci oral jak pipelin includ itacitinib uc ha
develop topic version ruxolitinib atop dermat ad vitiligo
ad million diagnos patient major million mild/moder form
look target mild/moder segment less bodi surfac area involv rux cream
data present eadv posit compar pfe eucrisa approv mild/mod ad
previou note
move data
quickli data expect
potenti fda submiss
expect potenti
launch
shown posit proof concept data evalu topic ruxolitinib ad compani look
present robust data note japan tobacco recent file approv topic
jak inhibitor treatment atop dermat japan sure us file plan
develop topic version ruxolitinib atop dermat ad vitiligo
wcd june unveil data evalu topic rux adult vitiligo studi met primari endpoint
improv bl facial vitiligo area sever index compar pbo
qd dose respons
primari endpoint pbo arm regist
also evalu
bid dose highest respons
respons
strong poc data vitiligo dose
first patient expect
data readout launch
compani estim vitiligo million patient opportun
studi includ two patient trial evalu bid cream vs vehicl primari endpoint f-
present strong proof-of-concept data vitiligo data set demonstr
improv patient
topic jakafi derm landscap
aim target
mild/moder segment
patient topic
formul hope
avoid toxic associ
oral jak inhibitor
topic approach ad
monitor
file japan nda
inci topic rux abil first
approv therapi vitiligo aclari topic
oral could pose competit threat
monitor
formul jakafi cream aim lower toxic issu seen oral jak inhibitor
although show strong data ad vitiligo remain competit horizon
note durat therapi vitiligo much longer intermitt use ad
week time seek develop partner
evalu pemigatinib inhibitor genet defin cancer
previous treat icca patient fusion rearrang pemigatinib demonstr orr
diseas control rate durat respons median
safeti grade hyperphosphatemia grade observ manag retin detach
observ patient clinic sequela
announc updat pemigatinib data esmo icca patient mutat
result support nda submiss fda
program arql
plan evalu pemigatinib across multipl tumor type
repres patient popul
posit data icca present esmo look submit nda
initi trial icca
repres much larger opportun patient
studi bladder cancer fgfr mutations/fus
look complet enrol present continu dose data mid-
cohort trial bladder cancer evalu pemigatinib keytruda vs pemigatinib vs
standard care
competit jnj balversa erdafitinib receiv fda approv fgfr mutat bladder
cancer drug receiv approv data set show orr durat
also current enrol tumor agnost studi patient opportun
evalu pemigatinib ultra-rar mpn cancer indic patient opportun
potenti first fda approv fgfr inhibitor icca larger
opportun exist bladder cancer solid tumor
look expand pemigatinib larger indic includ bladder cancer tumor agnost studi
howev appear fgfr inhibitor develop mani indic
advanc solid tumor fgfr alter
solid tumor fgfr genet alter
solid tumor fgfr abnorm
proof concept studi
compet jnj balversa approv bladder well number
development fgfr inhibitor bayer qed bridgebio arqul
lipid signal kinas part signal pathway control mani cellular function
cell growth metabol cytokin releas develop paraclisib inhibitor variou
oncolog autoimmun indic
paraclisib investig sever trial
follicular lymphoma
margin zone lymphoma
mantl cell lymphoma
hasnt spoken much program
initi data releas
pathway valid oncolog issu around
coliti limit util approach explor
variou dose regimen mitig coliti remain
seen program commerci attract
evalu parsaclisib pair
studi follow indic
sjogren syndrom diseas
immun system attack
salivari tear gland affect
us
diseas bodi produc
antibodi target red blood
cell estim preval per
evalu parsaclisib oncolog indic initi data well autoimmun diseas
concern around coliti sustain exposur class concern evalu intermitt
dose help address issu
evr isi rommel et al natur review immunolog zanella barcellini haematologica
addit program discuss oncolog pipelin opportun
antibodi drug licens shown evid clinic activ similar
respons rate compar approv therapi sever tumor type nsclc cervic cancer endometri cancer
evalu three registr trial msi-high endometri merkel cell carcinoma anal cancer
initi data
june enter agreement zlab licens drug greater china transact term
oral small-molecul inhibitor uniqu moa bind intern surfac
evalu earlier-stag cancer program includ gitr
evalu pipelin asset varieti oncolog indic provid sizabl market
wolter kluwer clinic drug inform inc wkcdi copyright wolter kluwer clinic drug inform inc wkcdi endors data
view opinion find express herein document materi prepar behalf evercor isi employe
npv
npv fcf-per-share
target market cap impli pt
target ev impli pt
growth rate
good sold
interest incom expens
loss debt redemption/oth
statement flow
depreci amort
loss gain
prepaid expens asset
accru current liabil
oper
sale market secur
matur market secur
purchas market secur
invest
proce issuanc common
repurchas convert note
financ
net inc cash cash equival
cash/equival begin
cash/equival end
pt base dcf use discount rate appli commerci
stage biotech compani termin growth rate includ contribut jakafi et gvhd well
olumi also includ meaning gener catch-al line item captur program fgfr inhibitor
risk includ increas competit threat jakafi/olumi continu aggress develop spend jakafi
patent expiri approach next decad
articl articl
time dissemin octob
analyst josh schimmer neeraj koduri angela ni maneka mirchandaney primarili respons prepar research report
attest follow view opinion render research report reflect person view subject
compani issuer part research analyst compens directli relat specif
recommend view research report
